{
  "CitationSubset": [
    "IM"
  ],
  "KeywordList": [
    [
      "Bukavu",
      "Congo",
      "SARS-CoV-2",
      "Seroprevalence"
    ]
  ],
  "GeneralNote": [],
  "OtherAbstract": [
    {
      "AbstractText": [
        "les tests s\u00e9rologiques anti-SARS-CoV-2 pourrait jouer un r\u00f4le majeur dans l\u00b4estimation de la pr\u00e9valence de la COVID-19. L\u00b4objectif \u00e9tait d\u00b4estimer la pr\u00e9valence de la COVID-19 dans la ville de Bukavu, \u00e0 l'Est de la R\u00e9publique D\u00e9mocratique du Congo, parmi les voyageurs et travailleurs.",
        "entre mai et ao\u00fbt 2020, les tests rapides Cellex qSARS-CoV-2 IgG/IgM (Cellex, Inc., USA), test immunologique \u00e0 flux lat\u00e9ral, ont \u00e9t\u00e9 utilis\u00e9s pour d\u00e9tecter et diff\u00e9rencier des anticorps anti-SARS-CoV-2 chez les voyageurs et les travailleurs en qu\u00eate d\u00b4un certificat m\u00e9dical.",
        "parmi 684 habitants de la ville de Bukavu d\u00e9pist\u00e9s de la COVID-19 (4,2% hispaniques, 2,8% autres africains, 0,9% asiatiques), la s\u00e9ropr\u00e9valence anti-SARS-CoV-2 \u00e9tait de 40,8% (IgG+/IgM+: 34,6%; IgG+/IgM-: 0,5%; IgG-/IgM+: 5,4%). La s\u00e9ropr\u00e9valence cumul\u00e9e des IgG anti-SARS-CoV-2 est pass\u00e9e de 24,5% \u00e0 35,2% de mai \u00e0 ao\u00fbt 2020. Les pr\u00e9dicteurs ind\u00e9pendants des anticorps anti-SARS-CoV-2 \u00e9taient l\u00b4\u00e2ge > 60 ans [OR ajust\u00e9= 2,07(1,26-3,38)] et la non-appartenance au personnel m\u00e9dical [OR ajust\u00e9= 2,28(1,22-4,26)]. Treize virgule neuf pour cent (13,9%) des s\u00e9ropositifs pour les SARS-CoV-2 \u00e9taient symptomatiques et hospitalis\u00e9s.",
        "la pr\u00e9sente \u00e9tude montre une s\u00e9ropr\u00e9valence tr\u00e8s \u00e9lev\u00e9e des anticorps anti-SARS-CoV-2 dans la ville de Bukavu, \u00e0 l\u00b4Est de la R\u00e9publique D\u00e9mocratique du Congo, parmi les voyageurs et travailleurs, pouvant impacter positivement sur l\u00b4immunit\u00e9 communautaire de la population \u00e9tudi\u00e9e. Ainsi, la prise en charge de la COVID-19 devrait \u00eatre contextualis\u00e9e en fonction des r\u00e9alit\u00e9s de chaque r\u00e9gion."
      ],
      "CopyrightInformation": "Copyright: Philippe Bianga Katchunga et al."
    }
  ],
  "SpaceFlightMission": [],
  "OtherID": [],
  "InvestigatorList": [],
  "PMID": "33889259",
  "DateCompleted": {
    "Year": "2021",
    "Month": "05",
    "Day": "03"
  },
  "DateRevised": {
    "Year": "2022",
    "Month": "04",
    "Day": "22"
  },
  "Article": {
    "ArticleDate": [
      {
        "Year": "2021",
        "Month": "01",
        "Day": "27"
      }
    ],
    "Language": [
      "fre"
    ],
    "ELocationID": [
      "93",
      "10.11604/pamj.2021.38.93.26663"
    ],
    "Journal": {
      "ISSN": "1937-8688",
      "JournalIssue": {
        "Volume": "38",
        "PubDate": {
          "Year": "2021"
        }
      },
      "Title": "The Pan African medical journal",
      "ISOAbbreviation": "Pan Afr Med J"
    },
    "ArticleTitle": "[Seroprevalence of SARS-CoV-2 antibodies among travellers and workers screened at the Saint Luc Clinic in Bukavu, a city in eastern Democratic Republic of the Congo, from May to August 2020].",
    "Pagination": {
      "StartPage": "93",
      "MedlinePgn": "93"
    },
    "Abstract": {
      "AbstractText": [
        "SARS-CoV-2 serology tests could play a crucial role in estimating the prevalence of COVID-19. The purpose of this study was to estimate the prevalence of COVID-19 among travellers and workers in Bukavu, a city in eastern Democratic Republic of the Congo.",
        "between May and August 2020, the Cellex qSARS-CoV-2 IgG/IgM Rapid Test (Cellex, Inc., USA), lateral flow immunoassay was used to rapidly detect and differentiate antibodies against SARS-CoV-2 among travellers and workers seeking medical certification.",
        "among the 684 residents of the city of Bukavu screened for COVID-19 (4.2% Hispanic, 2.8% other African, 0.9% Asian), the seroprevalence anti-SARS-CoV-2 antibodies was 40.8% (IgG+/IgM+: 34.6%; IgG+/IgM-: 0.5%; IgG-/IgM+: 5.4%). Cumulative seroprevalence of anti-SARS-CoV-2 IgG antibodies increased from 24.5% to 35.2% from May to August 2020. Independent predictors of SARS-CoV-2 antibodies were age > 60 years [adjusted OR = 2.07(1.26-3.38)] and non-membership of the medical staff [adjusted OR = 2.28 (1.22-4.26)]. Thirteen point nine percent of patients seropositive for SARS-CoV-2 antibodies were symptomatic and hospitalized.",
        "this study shows a very high seroprevalence of SARS-CoV-2 antibodies among travellers and workers in Bukavu, a city in eastern Democratic Republic of the Congo, which may positively affect community immunity in the study population. Thus, the management of COVID-19 should be contextualized according to local realities."
      ],
      "CopyrightInformation": "Copyright: Philippe Bianga Katchunga et al."
    },
    "AuthorList": [
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Clinique Saint-Luc de Bukavu, Bukavu, R\u00e9publique D\u00e9mocratique du Congo."
          },
          {
            "Identifier": [],
            "Affiliation": "Facult\u00e9 de M\u00e9decine, Universit\u00e9 Officielle de Bukavu, Bukavu, R\u00e9publique D\u00e9mocratique du Congo."
          }
        ],
        "LastName": "Katchunga",
        "ForeName": "Philippe Bianga",
        "Initials": "PB"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Clinique Saint-Luc de Bukavu, Bukavu, R\u00e9publique D\u00e9mocratique du Congo."
          }
        ],
        "LastName": "Murhula",
        "ForeName": "Aim\u00e9",
        "Initials": "A"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Clinique Saint-Luc de Bukavu, Bukavu, R\u00e9publique D\u00e9mocratique du Congo."
          }
        ],
        "LastName": "Akilimali",
        "ForeName": "Prince",
        "Initials": "P"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Clinique Saint-Luc de Bukavu, Bukavu, R\u00e9publique D\u00e9mocratique du Congo."
          }
        ],
        "LastName": "Zaluka",
        "ForeName": "Jean Claude",
        "Initials": "JC"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Clinique Saint-Luc de Bukavu, Bukavu, R\u00e9publique D\u00e9mocratique du Congo."
          }
        ],
        "LastName": "Karhikalembu",
        "ForeName": "Racine",
        "Initials": "R"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Clinique Saint-Luc de Bukavu, Bukavu, R\u00e9publique D\u00e9mocratique du Congo."
          }
        ],
        "LastName": "Makombo",
        "ForeName": "Mack",
        "Initials": "M"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Clinique Saint-Luc de Bukavu, Bukavu, R\u00e9publique D\u00e9mocratique du Congo."
          }
        ],
        "LastName": "Bisimwa",
        "ForeName": "Justin",
        "Initials": "J"
      },
      {
        "Identifier": [],
        "AffiliationInfo": [
          {
            "Identifier": [],
            "Affiliation": "Clinique Saint-Luc de Bukavu, Bukavu, R\u00e9publique D\u00e9mocratique du Congo."
          }
        ],
        "LastName": "Mubalama",
        "ForeName": "Eugene",
        "Initials": "E"
      }
    ],
    "PublicationTypeList": [
      "Journal Article"
    ],
    "VernacularTitle": "S\u00e9ropr\u00e9valence des anticorps anti-SARS-CoV-2 parmi les voyageurs et travailleurs d\u00e9pist\u00e9s \u00e0 la clinique Saint Luc de Bukavu, \u00e0 l\u00b4Est de la R\u00e9publique D\u00e9mocratique du Congo, de mai en ao\u00fbt 2020."
  },
  "MedlineJournalInfo": {
    "Country": "Uganda",
    "MedlineTA": "Pan Afr Med J",
    "NlmUniqueID": "101517926"
  },
  "ChemicalList": [
    {
      "RegistryNumber": "0",
      "NameOfSubstance": "Antibodies, Viral"
    }
  ],
  "MeshHeadingList": [
    {
      "QualifierName": [],
      "DescriptorName": "Adult"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Age Factors"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Aged"
    },
    {
      "QualifierName": [
        "blood"
      ],
      "DescriptorName": "Antibodies, Viral"
    },
    {
      "QualifierName": [
        "diagnosis",
        "epidemiology"
      ],
      "DescriptorName": "COVID-19"
    },
    {
      "QualifierName": [
        "epidemiology"
      ],
      "DescriptorName": "Democratic Republic of the Congo"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Female"
    },
    {
      "QualifierName": [
        "statistics & numerical data"
      ],
      "DescriptorName": "Hospitalization"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Humans"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Immunoassay"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Male"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Middle Aged"
    },
    {
      "QualifierName": [
        "immunology",
        "isolation & purification"
      ],
      "DescriptorName": "SARS-CoV-2"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Seroepidemiologic Studies"
    },
    {
      "QualifierName": [],
      "DescriptorName": "Travel"
    }
  ],
  "CoiStatement": "Les auteurs ne d\u00e9clarent aucun conflit d\u00b4int\u00e9r\u00eats."
}